![Immunohistochemistry: Complement Component C9 Antibody [NBP2-15952] - A generic staining of the vascular BMs was given by an antibody to the 7S domain of collagen IV a3 (C). Prominent staining for microvascular aneurisms was detected by staining with antibodies to C9 (B, C). The same treatment of vascular BM whole mounts from non-diabetic eyes did not show staining for these proteins (D). Image collected and cropped by CiteAb from the following publication (dx.plos.org/10.1371/journal.pone.0189857) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Complement-Component-C9-Antibody-Immunohistochemistry-NBP2-15952-img0010.jpg "Immunohistochemistry: Complement Component C9 Antibody [NBP2-15952] - A generic staining of the vascular BMs was given by an antibody to the 7S domain of collagen IV a3 (C). Prominent staining for microvascular aneurisms was detected by staining with antibodies to C9 (B, C). The same treatment of vascular BM whole mounts from non-diabetic eyes did not show staining for these proteins (D). Image collected and cropped by CiteAb from the following publication (dx.plos.org/10.1371/journal.pone.0189857) licensed under a CC-BY license.")
| Reactivity | Hu, Mu, RtSpecies Glossary |
| Applications | WB, ICC/IF, IHC |
| Clonality | Polyclonal |
| Host | Rabbit |
| Conjugate | Unconjugated |
| Immunogen | Recombinant protein encompassing a sequence within the center region of human Complement Component C9. The exact sequence is proprietary. |
| Localization | Membrane; Multi-pass membrane protein; Secreted; Membrane; Secreted |
| Isotype | IgG |
| Clonality | Polyclonal |
| Host | Rabbit |
| Gene | C9 |
| Purity | Antigen Affinity-purified |
| Innovator's Reward | Test in a species/application not listed above to receive a full credit towards a future purchase. |
| Dilutions |
|
|
| Theoretical MW | 63 kDa. Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors. |
|
| Publications |
|
| Storage | Aliquot and store at -20C or -80C. Avoid freeze-thaw cycles. |
| Buffer | PBS, 20% Glycerol |
| Preservative | 0.025% Proclin 300 |
| Purity | Antigen Affinity-purified |
| Publication using NBP2-15952 | Applications | Species |
|---|---|---|
| Halfter W, Moes S, Asgeirsson DO et al. Diabetes-related changes in the protein composition and the biomechanical properties of human retinal vascular basement membranes. PLoS ONE 2017-12-28 [PMID: 29284024] (ICC/IF, Human) | ICC/IF | Human |
Secondary Antibodies |
Isotype Controls |
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
![Western Blot: Complement Component C9 Antibody [NBP2-15952] - Sample (30 ug of whole cell lysate) A: THP-1 7. 5% SDS PAGE gel, diluted at 1:500.](http://images.novusbio.com/fullsize/Complement-Component-C9-Antibody-Western-Blot-NBP2-15952-img0002.jpg "Western Blot: Complement Component C9 Antibody [NBP2-15952] - Sample (30 ug of whole cell lysate) A: THP-1 7. 5% SDS PAGE gel, diluted at 1:500.")
![Immunocytochemistry/Immunofluorescence: Complement Component C9 Antibody [NBP2-15952] - HepG2 cells were fixed in 4% paraformaldehyde at RT for 15 min. Green: C9 stained by C9 antibody [N2C2-2], Internal diluted at 1:500. Blue: Hoechst 33342 staining.](http://images.novusbio.com/fullsize/Complement-Component-C9-Antibody-Immunocytochemistry-Immunofluorescence-NBP2-15952-img0003.jpg "Immunocytochemistry/Immunofluorescence: Complement Component C9 Antibody [NBP2-15952] - HepG2 cells were fixed in 4% paraformaldehyde at RT for 15 min. Green: C9 stained by C9 antibody [N2C2-2], Internal diluted at 1:500. Blue: Hoechst 33342 staining.")
![Western Blot: Complement Component C9 Antibody [NBP2-15952] - Human plasma (30 ug) was separated by 7.5% SDS-PAGE, and the membrane was blotted with C9 antibody [N2C2-2], Internal diluted at 1:500. The HRP-conjugated anti-rabbit IgG antibody (NBP2-19301) was used to detect the primary antibody.](http://images.novusbio.com/fullsize/Complement-Component-C9-Antibody-Western-Blot-NBP2-15952-img0005.jpg "Western Blot: Complement Component C9 Antibody [NBP2-15952] - Human plasma (30 ug) was separated by 7.5% SDS-PAGE, and the membrane was blotted with C9 antibody [N2C2-2], Internal diluted at 1:500. The HRP-conjugated anti-rabbit IgG antibody (NBP2-19301) was used to detect the primary antibody.")
![Western Blot: Complement Component C9 Antibody [NBP2-15952] - Rat plasma (50 ug) was separated by 10% SDS-PAGE, and the membrane was blotted with Complement Component C9 Antibody diluted at 1:1000. HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody.](http://images.novusbio.com/fullsize/Complement-Component-C9-Antibody-Western-Blot-NBP2-15952-img0006.jpg "Western Blot: Complement Component C9 Antibody [NBP2-15952] - Rat plasma (50 ug) was separated by 10% SDS-PAGE, and the membrane was blotted with Complement Component C9 Antibody diluted at 1:1000. HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody.")
![Western Blot: Complement Component C9 Antibody [NBP2-15952] - Mouse plasma (50 ug) was separated by 12% SDS-PAGE, and the membrane was blotted with Complement Component 9 antibody diluted at 1:1000. HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody,](http://images.novusbio.com/fullsize/Complement-Component-C9-Antibody-Western-Blot-NBP2-15952-img0007.jpg "Western Blot: Complement Component C9 Antibody [NBP2-15952] - Mouse plasma (50 ug) was separated by 12% SDS-PAGE, and the membrane was blotted with Complement Component 9 antibody diluted at 1:1000. HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody,")
![Immunocytochemistry/ Immunofluorescence: Complement Component C9 Antibody [NBP2-15952] - Staining of vascular BM whole mounts with antibodies to proteins detected in the proteome analysis.A generic staining of the vascular BMs was given by an antibody to the 7S domain of collagen IV alpha 3 (A, C, E, F, G). Prominent staining for microvascular aneurisms was detected by staining with antibodies to C9 (B, C), Fibronectin (FN, E), ApoE (F) & PRELP (G). The same treatment of vascular BM whole mounts from non-diabetic eyes did not show staining for these proteins (D). A norrin-specific staining is shown to be generic for the entire vascular BM whole mounts (H), the signal, however, being less prominent in vascular aneurisms (arrow in H). Staining of vascular BM whole mounts from non-diabetic eyes showed a clearly weaker staining for norrin, when compared to vascular whole mounts from non-diabetic donors. Bar: 25um. Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0189857), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-15952_rabbit-polyclonal-complement-component-c9-antibody-310202416121980.jpg "Immunocytochemistry/ Immunofluorescence: Complement Component C9 Antibody [NBP2-15952] - Staining of vascular BM whole mounts with antibodies to proteins detected in the proteome analysis.A generic staining of the vascular BMs was given by an antibody to the 7S domain of collagen IV alpha 3 (A, C, E, F, G). Prominent staining for microvascular aneurisms was detected by staining with antibodies to C9 (B, C), Fibronectin (FN, E), ApoE (F) & PRELP (G). The same treatment of vascular BM whole mounts from non-diabetic eyes did not show staining for these proteins (D). A norrin-specific staining is shown to be generic for the entire vascular BM whole mounts (H), the signal, however, being less prominent in vascular aneurisms (arrow in H). Staining of vascular BM whole mounts from non-diabetic eyes showed a clearly weaker staining for norrin, when compared to vascular whole mounts from non-diabetic donors. Bar: 25um. Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0189857), licensed under a CC-BY license. Not internally tested by Novus Biologicals.")
![Immunocytochemistry/ Immunofluorescence: Complement Component C9 Antibody [NBP2-15952] - Staining of vascular BM whole mounts with antibodies to proteins detected in the proteome analysis.A generic staining of the vascular BMs was given by an antibody to the 7S domain of collagen IV alpha 3 (A, C, E, F, G). Prominent staining for microvascular aneurisms was detected by staining with antibodies to C9 (B, C), Fibronectin (FN, E), ApoE (F) & PRELP (G). The same treatment of vascular BM whole mounts from non-diabetic eyes did not show staining for these proteins (D). A norrin-specific staining is shown to be generic for the entire vascular BM whole mounts (H), the signal, however, being less prominent in vascular aneurisms (arrow in H). Staining of vascular BM whole mounts from non-diabetic eyes showed a clearly weaker staining for norrin, when compared to vascular whole mounts from non-diabetic donors. Bar: 25um. Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0189857), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-15952_rabbit-polyclonal-complement-component-c9-antibody-31020241613612.jpg "Immunocytochemistry/ Immunofluorescence: Complement Component C9 Antibody [NBP2-15952] - Staining of vascular BM whole mounts with antibodies to proteins detected in the proteome analysis.A generic staining of the vascular BMs was given by an antibody to the 7S domain of collagen IV alpha 3 (A, C, E, F, G). Prominent staining for microvascular aneurisms was detected by staining with antibodies to C9 (B, C), Fibronectin (FN, E), ApoE (F) & PRELP (G). The same treatment of vascular BM whole mounts from non-diabetic eyes did not show staining for these proteins (D). A norrin-specific staining is shown to be generic for the entire vascular BM whole mounts (H), the signal, however, being less prominent in vascular aneurisms (arrow in H). Staining of vascular BM whole mounts from non-diabetic eyes showed a clearly weaker staining for norrin, when compared to vascular whole mounts from non-diabetic donors. Bar: 25um. Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0189857), licensed under a CC-BY license. Not internally tested by Novus Biologicals.")
![Immunocytochemistry/ Immunofluorescence: Complement Component C9 Antibody [NBP2-15952] - Staining of vascular BM whole mounts with antibodies to proteins detected in the proteome analysis.A generic staining of the vascular BMs was given by an antibody to the 7S domain of collagen IV alpha 3 (A, C, E, F, G). Prominent staining for microvascular aneurisms was detected by staining with antibodies to C9 (B, C), Fibronectin (FN, E), ApoE (F) & PRELP (G). The same treatment of vascular BM whole mounts from non-diabetic eyes did not show staining for these proteins (D). A norrin-specific staining is shown to be generic for the entire vascular BM whole mounts (H), the signal, however, being less prominent in vascular aneurisms (arrow in H). Staining of vascular BM whole mounts from non-diabetic eyes showed a clearly weaker staining for norrin, when compared to vascular whole mounts from non-diabetic donors. Bar: 25um. Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0189857), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-15952_rabbit-polyclonal-complement-component-c9-antibody-310202416113518.jpg "Immunocytochemistry/ Immunofluorescence: Complement Component C9 Antibody [NBP2-15952] - Staining of vascular BM whole mounts with antibodies to proteins detected in the proteome analysis.A generic staining of the vascular BMs was given by an antibody to the 7S domain of collagen IV alpha 3 (A, C, E, F, G). Prominent staining for microvascular aneurisms was detected by staining with antibodies to C9 (B, C), Fibronectin (FN, E), ApoE (F) & PRELP (G). The same treatment of vascular BM whole mounts from non-diabetic eyes did not show staining for these proteins (D). A norrin-specific staining is shown to be generic for the entire vascular BM whole mounts (H), the signal, however, being less prominent in vascular aneurisms (arrow in H). Staining of vascular BM whole mounts from non-diabetic eyes showed a clearly weaker staining for norrin, when compared to vascular whole mounts from non-diabetic donors. Bar: 25um. Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0189857), licensed under a CC-BY license. Not internally tested by Novus Biologicals.")
![N/A Complement Component C5a [Biotin]](https://images.novusbio.com/images2/DATA_Complement_Component_C5a_DY2037_ELISA_1753.jpg)
![N/A CXCL10/IP-10/CRG-2 [HRP]](https://images.novusbio.com/images2/DATA_CXCL10_DIP100_ELISA_723.jpg)
![N/A CXCL10/IP-10/CRG-2 [HRP]](https://images.novusbio.com/images2/DATA_CXCL10_DIP100_ELISA_724.jpg)
![N/A CXCL10/IP-10/CRG-2 [HRP]](https://images.novusbio.com/images2/CXCL10_DIP100_ELISA_121.jpg)
![Complement Component C2 Antibody [Unconjugated]](/sites/all/modules/enterprise-tech/et_datasheets/images/novus_guarantee.png "Complement Component C2 Antibody [Unconjugated]")
![Immunohistochemistry CD55/DAF Antibody [Unconjugated]](https://images.novusbio.com/images2/CD55_AF2009_Immunohistochemistry_6728.jpg)
![Immunocytochemistry CD55/DAF Antibody [Unconjugated]](https://images.novusbio.com/images2/CD55_AF2009_Immunocytochemistry__Immunofluorescence_23052.jpg)
![Western Blot: Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP] [NB7160] - Western blot showing vemurafenib treatment in BRAFV600E CRC cells inhibits fission mediator DRP1 with no significant effect on fusion proteins (Mfn1 & 2) using MFN-1 antibody (NBP1-51841) and corresponding secondary antibody, goat anti-rabbit IgG-HRP (NB7160). Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/33738242).](https://images.novusbio.com/images/Goat-anti-Rabbit-IgG-H+L-Secondary-Antibody-HRP-Western-Blot-NB7160-img0001.jpg "Western Blot: Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP] [NB7160] - Western blot showing vemurafenib treatment in BRAFV600E CRC cells inhibits fission mediator DRP1 with no significant effect on fusion proteins (Mfn1 & 2) using MFN-1 antibody (NBP1-51841) and corresponding secondary antibody, goat anti-rabbit IgG-HRP (NB7160). Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/33738242).")
![Flow Cytometry: Rabbit IgG Isotype Control [NBP2-24891] - Intracellular FACS analysis of mouse TLR6 polyclonal antibody (red), rabbit isotype control (green), RAW cells alone (shaded). Two micrograms of antibodies were used. Goat anti-rabbit FITC (Novus, 20302) was used as secondary.](https://images.novusbio.com/images/Rabbit--Mouse-IgG-Isotype-Control-Flow-Cytometry-NBP2-24891-img0001.jpg "Flow Cytometry: Rabbit IgG Isotype Control [NBP2-24891] - Intracellular FACS analysis of mouse TLR6 polyclonal antibody (red), rabbit isotype control (green), RAW cells alone (shaded). Two micrograms of antibodies were used. Goat anti-rabbit FITC (Novus, 20302) was used as secondary.")